Early effectivity of teduglutide for the treatment of short bowel sydrome – our first clinical experience


Early effectivity of teduglutide for the treatment of short bowel sydrome – our first clinical experience


Gombošová Laura1, Krivuš Juraj2, Lazúrová Ivica1, Dedinská Ivana3, Mokáň Marián2

1internal clinic of University hospital L.Pasteur and Faculty of Medicine of P.J. Šafárik University, Košice, Slovakia;2internal clinic of University Hospital of Martin and Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia; 3Transplant center of University Hospital of Martin and Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia


Background

Short bowel syndrome is an uncommon malabsorptive condition most frequently caused by massive surgical resection of the small intestine. Standard of care is home parenteral nutrition. Teduglutide, glucagon like peptide 2 analog, was approved to treat patients with short bowel syndrome, who are stable following a period of post-surgery intestinal adaptation.

Case presentation

We report two cases of patients with short bowel syndrome on home parenteral nutrition,  treated with teduglutide, novel advanced therapy. We monitored the effectiveness and tolerance of the new treatment.

Conclusion

Teduglutide increases intestinal absorption, causes cryptal hyperplasia, villous hypertrophy, angiogenesis, and allows weaning from parenteral nutrition. We confirmed the early onset of treatment effectiveness in the 4th month. Early effectiveness of treatment allowed a reduction in the volume of home parenteral nutrition with an improvement in quality of life.


Keywords: short bowel syndrome, teduglutide, glucagon like peptide 2, home parenteral nutrition


Free Full-text PDF


How to cite this article:

Gombošová Laura, Krivuš Juraj, Lazúrová Ivica, Dedinská Ivana, Mokáň Marián. Early effectivity of teduglutide for the treatment of short bowel sydrome – our first clinical experience. International Journal of Case Reports, 2021, 5:230. DOI: 10.28933/ijcr-2021-06-2805


References:

1. Massironi S, Cavalcoli F, Rausa E, Invernizzi P, Braga M, Vecchi M. Understanding short bowel syndrome: Current status and future perspectives. Dig Liv Dis. 2020; 52: 253–261.
2. Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015; 34:171– 80.
3. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016; 35[2]: 247-307.
4. Pironi L, Boeykens K, Bozzeti F, Joly F, Klek S, Lal S, et al. ESPEN guideline on home parenteral nutrition. Clin Nutr. 2020; 1645-1666.
5. Brubaker PL, Why Recycling Matters: Glucagon Like Peptide 2 and the Regulation of Intestinal Sodium and Fluid Absorption. Dig Dis Sci. 2020; 65:3422–3424.
6. Jeppessen PB, Pertkiewitz M, Messing B, Iyer K, Seidner DL, O´Keefe SJ, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterol. 2012; 143[6]:1473-1481.
7. Vipperla K, O´Keefe SJ. Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block. Clin Exp Gastroenterol. 2014; 7: 489–495.
8. Schoeler M, Klag T, Wendler J, Bernhard S, Adolph M, Kirschniak A, et al. GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting. Ther Adv Gastroenterol 2018; 11: 1–11.
9. Pape UF, Iyer KR, Jeppesen PB, Kunecki M, Pironi L, Schneider SM et al. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trial. Ther Adv Gastroenterol. 2020; 13: 1–18.
10. Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide–analyses from a randomised, placebo-controlled study. Clin Nutr. 2013; 32 [5]:713-21.


Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).



This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.